title: Rituximab treatment for nonparaneoplastic autoimmune retinopathy.
authors.affiliation: National Eye Institute, Bethesda, Md.
authors.forename: Austin
authors.initials: A
authors.lastname: Fox
authors.affiliation: National Eye Institute, Bethesda, Md.
authors.forename: Brett
authors.initials: B
authors.lastname: Jeffrey
authors.affiliation: National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Md.
authors.forename: Sarfaraz
authors.initials: S
authors.lastname: Hasni
authors.affiliation: National Eye Institute, Bethesda, Md; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Md.
authors.forename: Robert
authors.initials: R
authors.lastname: Nussenblatt
authors.affiliation: National Eye Institute, Bethesda, Md; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Md. Electronic address: senh@nei.nih.gov.
authors.forename: H Nida
authors.initials: HN
authors.lastname: Sen
mesh_terms: D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004596:Electroretinography; D005074:Evoked Potentials, Visual; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008875:Middle Aged; D059545:Paraneoplastic Syndromes, Ocular / Q000188:drug therapy; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000069283:Rituximab / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014794:Visual Fields
chemical_list: D007155:Immunologic Factors; D000069283:Rituximab